Document is current
Any future updates will be listed below
-
Authors
Olah, Csilla https://orcid.org/0000-0002-4775-2432
Mairinger, Fabian
Wessolly, Michael
Joniau, Steven https://orcid.org/0000-0003-3195-9890
Spahn, Martin
Kruithof-de Julio, Marianna
Hadaschik, Boris
Soós, Aron
Nyirády, Péter
Győrffy, Balázs
Reis, Henning
Szarvas, Tibor https://orcid.org/0000-0002-6321-0799
-
Funding
Funding for this research was provided by:
National Research, Development and Innovation Office of Hungary
- License Information
-
More Information
Article History
Received: 13 May 2024
Revised: 28 October 2024
Accepted: 31 October 2024
First Online: 14 November 2024
Competing interests
: BH: Advisory boards for Janssen, Bayer, ABX, Lightpoint, Amgen, MSD, Pfizer, Novartis. Invited speaker for Accord, Astellas, Janssen R&D. Honoraria from Uromed. Research funding from AAA/Novartis, Bristol Myers Squibb, and German Research Foundation. Leadership roles for DKG AUO and DGU. The authors declare no potential conflicts of interest with the present project and publication.
: The study was performed in compliance with the Declaration of Helsinki and the institutional ethics committees approved the study protocol (21-9991-BO and KEK-BE128/2015).
